Vertex’s IgA nephropathy drug derisked after Novartis, Vera approvals

Summary

Vertex's povetacicept for IgA nephropathy is under FDA review with a target decision date of November 30, 2026. The drug's market entry is considered derisked following recent FDA approvals of competing therapies Fabhalta (Novartis) and Trutakna (Vera Therapeutics).